Today we're announcing a major round of investment that will allow Rylivo to significantly expand its team, computational infrastructure, and therapeutic programs over the coming years. The financing closes a key milestone since our founding and reflects strong validation of our approach to combining foundational machine learning with structural biology and chemistry.
Drug discovery has historically been slow, expensive, and uncertain. We believe the most consequential changes to medicine over the coming decade will come from treating biology as an information problem — and bringing computation, data, and design to bear at every step of the discovery pipeline.
What this means for our research
The Series A funds three priorities. First, we will scale our platform team and the foundation models that sit at its core, with continued investment in protein structure, dynamics, and chemical-space modelling. Second, we will expand our wet-lab capabilities so that every assay we run sharpens the next prediction. Third, we will advance our internal therapeutic programs and continue to partner with leading institutions on areas of high unmet need.
Joining us
We are hiring across machine learning, computational chemistry, structural biology, and software engineering. If our mission resonates, we'd love to hear from you — see open roles or get in touch directly.